ArticleJournal of gastroenterology2025

Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Ryoichi Miura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.